<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01839019</url>
  </required_header>
  <id_info>
    <org_study_id>3099003</org_study_id>
    <nct_id>NCT01839019</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability Study With Single Ascending Doses of ODM-102</brief_title>
  <official_title>Safety, Tolerability and Pharmacokinetics of Single Escalating Doses of ODM-102: A Randomised, Double-blind, Placebo-controlled, Single Centre Study in Healthy Males</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Orion Corporation, Orion Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Orion Corporation, Orion Pharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the safety and tolerability of escalating single&#xD;
      doses of ODM-102 in healthy volunteers&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety measures, i.e. assessing adverse events, vital signs, ECG and safety laboratory values</measure>
    <time_frame>about a month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>5 days per period</time_frame>
    <description>Explore the PK profile (e.g. Cmax, tmax, AUC, t1/2), screen circulating metabolites and determine protein binding.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Each subject will receive 2 single doses of study drug, either both of them active doses or the other placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ODM-102</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each subject will receive 2 single doses of study drug, either both of them active doses or the other placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ODM-102</intervention_name>
    <description>Single dose escalation</description>
    <arm_group_label>ODM-102</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for ODM-102</intervention_name>
    <description>Single dose escalation</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent (IC) obtained.&#xD;
&#xD;
          -  Good general health ascertained by detailed medical history and physical examination.&#xD;
&#xD;
          -  Finnish-speaking males between 18 and 45 years of age (inclusive).&#xD;
&#xD;
          -  Body mass index (BMI) between 18.0-30.5 kg/m2 (inclusive).&#xD;
&#xD;
          -  Weight 55.0-100.0 kg (inclusive).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Suspected poor compliance or inability to communicate well with the investigator.&#xD;
&#xD;
          -  Veins unsuitable for repeated venipuncture.&#xD;
&#xD;
          -  Evidence of clinically significant cardiovascular, renal, hepatic, haematological,&#xD;
             gastro-intestinal, pulmonary, metabolic-endocrine, neurological, urogenital or&#xD;
             psychiatric disease as judged by the investigator.&#xD;
&#xD;
          -  Any condition requiring regular concomitant drug treatment, including herbal products,&#xD;
             or likely to need any concomitant drug treatment during the study.&#xD;
&#xD;
          -  Susceptibility to severe allergic reactions.&#xD;
&#xD;
          -  Intake of any medication that could affect the outcome of the study within 2 weeks&#xD;
             prior to the first study drug administration or within less than 5 times the&#xD;
             elimination half-life of the medication.&#xD;
&#xD;
          -  Regular consumption of more than 21 units of alcohol per week (1 unit = 4 cl spirits,&#xD;
             about 13 g of alcohol).&#xD;
&#xD;
          -  Current use of nicotine-containing products more than 5 cigarettes or equivalent/day.&#xD;
&#xD;
          -  Inability to refrain from using nicotine-containing products during the stay in the&#xD;
             study centre.&#xD;
&#xD;
          -  Inability to refrain from consuming caffeine-containing beverages during the first 24&#xD;
             hours after treatment administration e.g. propensity to experience headache when&#xD;
             abstaining from caffeine-containing beverages.&#xD;
&#xD;
          -  Blood donation or loss of a significant amount of blood within 2 months prior to the&#xD;
             screening visit.&#xD;
&#xD;
          -  Abnormal 12-lead ECG finding of clinical relevance after 10 min rest in supine&#xD;
             position at the screening visit&#xD;
&#xD;
          -  HR &lt; 45 beats/minute or &gt; 90 beats/minute after 10 minutes rest in supine position at&#xD;
             the screening visit.&#xD;
&#xD;
          -  At the screening visit, systolic BP &lt; 90 mmHg or &gt; 140 mmHg after 10 minutes in supine&#xD;
             position, diastolic BP &lt; 50 mmHg or &gt; 90 mmHg after 10 minutes in supine position, or&#xD;
             symptomatic orthostatic hypotension, or decrease of ≥ 20 mmHg of systolic BP or&#xD;
             decrease of ≥ 10 mmHg of diastolic BP after 3 minutes in standing position.&#xD;
&#xD;
          -  Abnormal 24-hour Holter ECG recording of possible or confirmed clinical relevance&#xD;
&#xD;
          -  Any abnormal laboratory value, vital sign, or physical examination finding, which may&#xD;
             in the opinion of the investigator interfere with the interpretation of the test&#xD;
             results or cause a health risk to the subject if he takes part in the study.&#xD;
&#xD;
          -  Suspected current use of illicit drugs (according to medical history enquiry or&#xD;
             physical examination), positive drug screen or history of long-term drug abuse.&#xD;
&#xD;
          -  Positive serology to human immunodeficiency virus antigen/antibodies (HIVAgAb),&#xD;
             hepatitis B virus surface antigen (HBsAg) or hepatitis C virus antibodies (HCVAb).&#xD;
&#xD;
          -  Participation in another clinical drug study within 3 months prior to the first&#xD;
             treatment administration in this study.&#xD;
&#xD;
          -  Any other condition that in the opinion of the investigator would interfere with the&#xD;
             evaluation of the results or constitute a health risk for the subject.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mika Scheinin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Research Services Turku, CRST</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Research Services Turku, CRST</name>
      <address>
        <city>Turku</city>
        <zip>20520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <study_first_submitted>April 17, 2013</study_first_submitted>
  <study_first_submitted_qc>April 19, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 24, 2013</study_first_posted>
  <last_update_submitted>February 7, 2014</last_update_submitted>
  <last_update_submitted_qc>February 7, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 10, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy volunteers</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

